PaxMedica Inc PXMD shares are trading higher by 175% to $8.39 Tuesday morning after the company announced research findings in the Annals of General Psychiatry regarding a study on low-dose suramin intravenous infusions as a potential treatment for Autism Spectrum Disorder.
The study involved 52 boys aged 4-15 with moderate to severe ASD and demonstrated promising results in improving core symptoms, particularly with the 10 mg/kg suramin infusion.
The study's main objective was to assess the effectiveness and safety of suramin intravenous infusions. The group receiving a 10 mg/kg suramin dose showed promising improvements in core symptoms.
Additionally, statistically significant enhancements were observed in the Clinical Global Impressions-Improvement (CGI-I) scale in this 10 mg/kg group when compared to the placebo group.
The company says this research represents a significant advancement in understanding ASD treatment options, with the company committed to improving the lives of those with ASD.
See Also: Uber Reports Q3 Results
According to data from Benzinga Pro, PaxMedica has a 52-week high of $69.22 and a 52-week low of $2.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
